DERMDERMHealthcare · Drug Manufacturers - Specialty & Generic

DERM Stock Forecast: Journey Medical Corp. Price Predictions for 2026-2027

Last close, 18 Nov 2026
$3.70
−5.13% on the day

The 3 Wall Street analysts covering Journey Medical Corp. hold a median 12-month price target of $13 — +251.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 58 of 100 as at 17 Nov 2026 — in the upper half.

Market cap
$110.1M
Ticker Nerd rank
58/ 100
Median analyst target
$13
Analysts covering
3
Revenue$18.5M+23.3% y/y
Operating income$456K
Net income−$312K
Free cash flow−$1.7M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.7%
1M
−25.5%
YTD
−52.0%
1Y
−53.5%
From 52W high
−60.0%
From 52W low
0.0%
$3.70
$9.26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DERM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Journey Medical Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 17 Nov 2026
58/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
89
Growth
81
Quality
80
Volatility
73
Size
72
Momentum
39
Revisions
34
Issuance
29
Accruals
15

Value (89): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (15): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

DERM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DERM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26DERMHigh $13Median $13Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $12Median $13High $13

The green dot is the last close — the median target sits +251.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 Nov 2026B. Riley SecuritiesReiteratesBuy$15 → $13
26 Oct 2026HC Wainwright & Co.ReiteratesBuy$13
26 Oct 2026HC Wainwright & Co.ReiteratesBuy—
13 Aug 2026B. Riley SecuritiesReiteratesBuy$12 → $15
13 Aug 2026B. Riley SecuritiesReiteratesBuy—
26 Mar 2026HC Wainwright & Co.ReiteratesBuy$13
26 Mar 2026HC Wainwright & Co.ReiteratesBuy—
25 Aug 2025HC Wainwright & Co.InitiatesBuy—
13 Aug 2025Lake StreetMaintainsBuy—
30 July 2025B. Riley SecuritiesMaintainsBuy—
6 Sept 2024Lake StreetInitiatesBuy$9.00
22 Aug 2024Rodman & RenshawInitiatesBuy$9.00
28 June 2024Roth MKMReinstatesBuy$11
16 Feb 2024Alliance Global PartnersInitiatesBuy—
7 Sept 2023B. Riley SecuritiesReiteratesBuy—
12 July 2023B. Riley SecuritiesMaintainsBuy—
23 May 2023B. Riley SecuritiesMaintainsBuy—
30 Mar 2023B. Riley SecuritiesReiteratesBuy—
25 Feb 2022Cantor FitzgeraldInitiatesOverweight—
16 Dec 2021Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

DERM appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

DERM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Nov 2026, Journey Medical Corp. returned −53.5% against +12.2% for the S&P 500, dividends included.

DERM vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26DERMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DERM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Journey Medical Corp. (DERM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
39.1×

Cheaper than 19% of US stocks

Price / sales
1.6×

Cheaper than 53% of US stocks

Price / book
3.4×

Cheaper than 24% of US stocks

EV / EBITDA
53.5×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
7.6%

Higher than 47% of US stocks

Earnings growth (YoY)
23.3%

Higher than 62% of US stocks

Gross margin
66.8%

Higher than 80% of US stocks

Operating margin
−2.9%

Higher than 29% of US stocks

Net margin
−7.3%

Higher than 21% of US stocks

Returns & dividend
Return on equity
−17.6%

Higher than 32% of US stocks

Return on assets
−1.3%

Higher than 38% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Journey Medical Corp. (DERM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Journey Medical Corp. has a market value of $110.1M and an enterprise value of $113.4M.

  • Revenue in the twelve months to 30 June 2026: $68.2M. The latest quarter grew 7.6% year on year.

  • Net income over the same four quarters: −$6.1M, a −9.0% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$7.5M.

  • Shares outstanding: 27.7M.

  • Trailing P/E: 39.1×; forward P/E: −65.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Journey Medical Corp. employs 58 people — $1.2M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

DERM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
DERMJourney Medical Corp.$110.1M58
AKBAAkebia Therapeutics, Inc.$107.3M44
BGMBGM Group Ltd.$108.6M43
ORGOOrganogenesis Holdings, Inc.$103.0M30
CPIXCumberland Pharmaceuticals, Inc.$86.9M75
ZYBTZhengye Biotechnology Holding Ltd.$77.5M54
ANIKAnika Therapeutics, Inc.$172.2M98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Journey Medical Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DERM news & analysis

Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates

Zacks Investment Research · 12 Nov 2026negative

Journey Medical reported a Q3 loss of $0.05 per share, wider than the Zacks Consensus Estimate of a $0.03 loss. The loss was narrower than the $0.09 per share loss reported a year earlier.

Why it matters — The per-share loss exceeded the consensus estimate, while improving year over year, giving DERM watchers two points of comparison for the quarter.

What Journey Medical (DERM) Said on Its Q3 Earnings Call

MarketBeat · 12 Nov 2026positive

Journey Medical reported higher third-quarter revenue and a narrower net loss, alongside growth in sales of its rosacea treatment Emrosi. Executives said broader insurance coverage could support the product’s pricing and revenue in 2027.

Why it matters — Investors following DERM may note Emrosi’s sales growth and the potential role of broader insurance coverage in its future pricing and revenue.

Journey Medical Corporation to Announce Third Quarter 2026 Financial Results on November 12, 2026

GlobeNewsWire · 5 Nov 2026neutral

Journey Medical Corporation said it will announce its third-quarter 2026 financial results on November 12, 2026. The company will host a conference call that day at 4:30 p.m. ET to discuss the results and provide a corporate update.

Why it matters — DERM watchers can note the date and time when the company plans to share its financial results and corporate update.

FAQ

Frequently asked questions about DERM stock

What is the DERM stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Journey Medical Corp. have a median 12-month price target of $13, with estimates ranging from $12 to $13. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DERM stock a buy right now?

Of the 3 analysts covering Journey Medical Corp., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Journey Medical Corp. 58 out of 100 across roughly 4,600 US stocks as at 17 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DERM?

As at 17 Nov 2026, Journey Medical Corp. ranks 58 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (89 of 100).

Will DERM stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +251.4% from the last close, and Ticker Nerd's factor model ranks Journey Medical Corp. 58 out of 100 as at 17 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DERM stock forecast for 2030?

No analyst covering Journey Medical Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DERM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $13 over the next 12 months.

How has DERM stock performed over the past year?

Journey Medical Corp. returned -53.5% over the 12 months to 18 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Journey Medical Corp. do?

Journey Medical Corp. Common Stock represents the equity of Journey Medical Corporation, a commercial-stage pharmaceutical company focused on developing, marketing, and selling prescription products for dermatological conditions in the United States.

What is the latest news on DERM?

The most recent item we track (Seeking Alpha, 13 Nov 2026): "Journey Medical Corporation (DERM) Q3 2026 Earnings Call Transcript". Seeking Alpha published the transcript of Journey Medical Corporation’s Q3 2026 earnings call.

Company

About Journey Medical Corp.

Journey Medical Corp. Common Stock represents the equity of Journey Medical Corporation, a commercial-stage pharmaceutical company focused on developing, marketing, and selling prescription products for dermatological conditions in the United States. The company’s portfolio includes branded and authorized generic treatments used in areas such as acne, hyperhidrosis, fungal infections, and other skin disorders. Its current product lineup includes therapies such as Qbrexza, Accutane, Amzeeq, Targadox, Ximino, Zilxi, Exelderm, and Luxamend, reflecting a business centered on specialty dermatology care. Journey Medical Corp. serves a focused market within the broader pharmaceutical sector by commercializing FDA-approved products designed for physician-prescribed use. The stock is associated with a small-cap healthcare company whose role in the market is tied to the distribution and commercialization of dermatology medicines rather than broad consumer health products.

CEO Mr. Claude Maraoui · 58 employees · United States · https://journeymedicalcorp.com